GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Goldenwell Biotech GWLL · USD

N/A · US listing · 🇺🇸 United States

Compare

0.55

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$139

FY2019FY2024

Net income

−$131,498

FY2019FY2024

Free cash flow

−$123,080

FY2019FY2024

Shareholders' equity

−$47,241

FY2019FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$139$2,340$47,800$15,967——
Gross profit$64$1,108$25,186$8,388——
Operating income−$123,098−$116,895−$985,105−$118,267−$6,368−$7,803
Net income−$131,498−$116,895−$985,097−$116,981−$6,324−$6,933
Diluted earnings per share-0.00-0.00-0.01-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$224,192$228,057$248,400$460,979$248,569$246,593
Cash and short-term investments$49,404$53,231$45,996$213,556$248,569$246,593
Total liabilities$271,433$143,334$46,782$159,265——
Debt$95,588$141,923$25,372$47,779——
Shareholders' equity−$47,241$84,723$201,618$301,714$248,569$246,593
Shares outstanding99m96m112m96m99m99m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$123,077−$114,689−$1.1m−$205,138−$6,324−$6,933
Capital spending−$3−$1————
Free cash flow−$123,080−$114,690−$1.1m−$205,138−$6,324−$6,933

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue−$1,860—$55$25,000$37,500−$158−$158—
Gross profit$12—$12$25,000$37,500−$85−$85−$149
Operating income−$34,776−$31,335−$22,895−$5,885−$3,120−$32,277−$19,136−$23,065
Net income−$36,876−$17,606−$199,740−$7,985−$5,220−$34,377−$27,536−$23,065
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$28,978$18,754$36,120$220,410$251,295$191,915$224,192$179,432
Cash and short-term investments$26,775——$45,622$76,507$17,127—$4,755
Debt$140,588$95,588$95,588$95,588$95,588$95,588$95,588—
Shareholders' equity−$343,713−$361,318−$343,713−$143,974−$86,838−$81,618−$47,241−$19,239

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-89.5%——
Operating income-51.4%77.9%—
Net income-33.0%115.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin39.2%52.4%——
Operating margin-121868.0%-2659.1%——
Net margin-220602.6%-3039.6%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-559.6-29.0-9.3-1.5
Price to sales——465.131.1

Share price return

Finished calendar years

2025202420232022
Return4400%241%-15%0%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.